S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
Log in
NASDAQ:KIN

Kindred Biosciences Stock Forecast, Price & News

$4.86
-0.07 (-1.42 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.65
Now: $4.86
$5.05
50-Day Range
$3.71
MA: $4.49
$5.15
52-Week Range
$3.11
Now: $4.86
$11.93
Volume224,496 shs
Average Volume333,293 shs
Market Capitalization$191.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.19
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
Kindred Biosciences logo

MarketRank

Overall MarketRank

1.54 out of 5 stars

Medical Sector

378th out of 1,922 stocks

Pharmaceutical Preparations Industry

197th out of 771 stocks

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901
Employees156
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.26 million
Book Value$2.10 per share

Profitability

Net Income$-61,390,000.00

Miscellaneous

Market Cap$191.93 million
Next Earnings Date3/15/2021 (Estimated)
OptionableOptionable
$4.86
-0.07 (-1.42 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

How has Kindred Biosciences' stock price been impacted by COVID-19?

Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KIN stock has decreased by 39.9% and is now trading at $4.86.
View which stocks have been most impacted by COVID-19
.

Is Kindred Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kindred Biosciences stock.
View analyst ratings for Kindred Biosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Kindred Biosciences?

Wall Street analysts have given Kindred Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kindred Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Kindred Biosciences
.

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) announced its quarterly earnings results on Monday, November, 9th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.31). The biopharmaceutical company earned $1.04 million during the quarter, compared to the consensus estimate of $0.57 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 25.42% and a negative net margin of 62.50%.
View Kindred Biosciences' earnings history
.

What price target have analysts set for KIN?

6 equities research analysts have issued twelve-month target prices for Kindred Biosciences' stock. Their forecasts range from $9.00 to $13.00. On average, they expect Kindred Biosciences' share price to reach $10.56 in the next twelve months. This suggests a possible upside of 117.3% from the stock's current price.
View analysts' price targets for Kindred Biosciences
or view Wall Street analyst' top-rated stocks.

Who are some of Kindred Biosciences' key competitors?

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX).

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the following people:
  • Dr. Richard Chin, Co-Founder, Pres, CEO & Director (Age 53, Pay $899k)
  • Ms. Denise M. Bevers, Co-Founder & Director (Age 53, Pay $633.13k)
  • Ms. Wendy K. Wee, CFO & Sec. (Age 67, Pay $438.15k)
  • Dr. Hangjun Zhan, Chief Scientific Officer (Age 60, Pay $432.98k)
  • Ms. Katja Buhrer, Chief of Staff, VP of Corp. Devel. & Investor Relations

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $4.86.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $191.93 million and generates $4.26 million in revenue each year. The biopharmaceutical company earns $-61,390,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Kindred Biosciences employs 156 workers across the globe.

What is Kindred Biosciences' official website?

The official website for Kindred Biosciences is kindredbio.com.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.